CD47 and neoplasm: Specifically, we showed that pharmacological inhibition of ENO1 suppressed cell proliferation and tumor growth both in vitro and in vivo, but the ENOblock inhibitor was more effective in the CRC cells with higher level of CD47, indicating that CD47-high CRC patients might be more sensitive to ENO1 targeting therapy.